| Reviewing the significance of blood–brain barrier disruption in multiple sclerosis pathology and treatment R Balasa, L Barcutean, O Mosora, D Manu International journal of molecular sciences 22 (16), 8370, 2021 | 124 | 2021 |
| The action of TH17 cells on blood brain barrier in multiple sclerosis and experimental autoimmune encephalomyelitis R Balasa, L Barcutean, A Balasa, A Motataianu, C Roman-Filip, D Manu Human immunology 81 (5), 237-243, 2020 | 88 | 2020 |
| Oxidative stress in amyotrophic lateral sclerosis: synergy of genetic and environmental factors A Motataianu, G Serban, L Barcutean, R Balasa International Journal of Molecular Sciences 23 (16), 9339, 2022 | 42 | 2022 |
| Autoimmune encephalitis in COVID-19 infection: our experience and systematic review of the literature A Stoian, M Stoian, Z Bajko, S Maier, S Andone, RA Cioflinc, A Motataianu, ... Biomedicines 10 (4), 774, 2022 | 35 | 2022 |
| Astrocyte involvement in blood–brain barrier function: a critical update highlighting novel, complex, neurovascular interactions DR Manu, M Slevin, L Barcutean, T Forro, T Boghitoiu, R Balasa International Journal of Molecular Sciences 24 (24), 17146, 2023 | 26 | 2023 |
| Natalizumab Changes The Peripheral Profile Of The Th17 Panel In Ms Patients: New Mechanisms Of Action. RI Bălașa, S Mihaela, S Voidăzan, LI Bărcuțean, Z Bajko, A Huțanu, ... CNS & neurological disorders drug targets, 2017 | 24 | 2017 |
| Stroke secondary to giant‑cell arteritis: A literature review Z Bajko, R Balasa, S Maier, A Motataianu, L Barcutean, S Andone, ... Experimental and Therapeutic Medicine 22 (2), 1-7, 2021 | 22 | 2021 |
| Clinical and serological biomarkers of treatment's response in multiple sclerosis patients treated continuously with interferonβ-1b for more than a decade LI Bărcuţean, A Romaniuc, S Maier, Z Bajko, A Moţăţăianu, H Adina, ... CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS …, 2018 | 18 | 2018 |
| INTERFERON-β 1A, AN IMMUNOMODULATOR IN RELAPSING REMITTING MULTIPLE SCLEROSIS PATIENTS. THE EFFECT ON PRO-INFLAMMATORY CYTOKINES. S Maier, A Motataianu, L Barcutean, A Balint, A Hutanu, B Zoltan, A Stoian, ... Farmacia 68 (1), 2020 | 16 | 2020 |
| Gender differences in risk factor profile and clinical characteristics in 89 consecutive cases of cerebral venous thrombosis Z Bajko, A Motataianu, A Stoian, L Barcutean, S Andone, S Maier, ... Journal of Clinical Medicine 10 (7), 1382, 2021 | 15 | 2021 |
| Malignant middle cerebral artery infarction secondary to traumatic bilateral internal carotid artery dissection. A case report Z Bajkó, R Bălaşa, A Moţăţăianu, L Bărcuţean, A Stoian, N Stirbu, S Maier The Journal of Critical Care Medicine 2 (3), 135-141, 2016 | 15 | 2016 |
| High‑dose intravenous immunoglobulins as a therapeutic option in critical illness polyneuropathy accompanying SARS‑CoV‑2 infection: A case‑based review of the literature A Stoian, Z Bajko, S Maier, RA Cioflinc, BL Grigorescu, A Moțățăianu, ... Experimental and Therapeutic Medicine 22 (4), 1-11, 2021 | 14 | 2021 |
| Neuroprotection in Stroke—Focus on the Renin-Angiotensin System: A Systematic Review S Andone, Z Bajko, A Motataianu, S Maier, L Barcutean, R Balasa International Journal of Molecular Sciences 23 (7), 3876, 2022 | 13 | 2022 |
| Postpartum cerebral venous thrombosis—A single-center experience Z Bajko, A Motataianu, A Stoian, L Barcutean, S Andone, S Maier, ... Brain Sciences 11 (3), 327, 2021 | 13 | 2021 |
| Neuroimmunity in amyotrophic lateral sclerosis: focus on microglia A Motataianu, L Barcutean, R Balasa Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 21 (3-4), 159-166, 2020 | 13 | 2020 |
| The direct deleterious effect of Th17 cells in the nervous system compartment in multiple sclerosis and experimental autoimmune encephalomyelitis: One possible link between … R Balasa, S Maier, L Barcutean, A Stoian, A Motataianu Revista Romana de Medicina de Laborator 28 (1), 9-17, 2020 | 12 | 2020 |
| The main determinants for suicidal ideation in a Romanian cohort of multiple sclerosis patients A Romaniuc, R Bălaşa, N Ştirbu, S Maier, S Andone, Z Bajko, L Bărcuţean, ... Behavioural neurology 2020 (1), 2594702, 2020 | 12 | 2020 |
| Recent progress in the identification of early transition biomarkers from relapsing-remitting to progressive multiple sclerosis S Maier, L Barcutean, S Andone, D Manu, E Sarmasan, Z Bajko, R Balasa International Journal of Molecular Sciences 24 (5), 4375, 2023 | 11 | 2023 |
| UNDERSTANDING THE MECHANISM OF ACTION OF INTRAVENOUS IMMUNOGLOBULINS: A TEN YEARS EXPERIENCE IN TREATING GUILLAIN BARRÉ SYNDROME. A Stoian, A Motataianu, L Barcutean, S Maier, Z Bajko, S Voidazan, ... Farmacia 68 (3), 2020 | 10 | 2020 |
| The Immunomodulatory Potential of Short-Chain Fatty Acids in Multiple Sclerosis L Barcutean, S Maier, M Burai-Patrascu, L Farczadi, R Balasa International Journal of Molecular Sciences 25 (6), 3198, 2024 | 8 | 2024 |
Rodica BălașaProfesor Universitar, Universitatea de Medicină și Farmacie Târgu Mureș在 umftgm.ro 的电子邮件经过验证
